Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of IMR-687 versus placebo in adults with sickle cell disease
PACTR202012920757784Phase 2Recruiting
- Sponsor
- Imara Therapeutics
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised trial in sickle cell disease (SCD) comparing IMR-687 with Placebo (2 arms). Primary endpoints: Fetal hemoglobin response and Safety. Started Jan 2021; status: recruiting.
02
Drugs
tovinontrine
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on PACTR202012920757784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202012920757784.